Idexx Laboratories price target raised to $655 from $605 at Barclays

Barclays analyst Balaji Prasad raised the firm’s price target on Idexx Laboratories to $655 from $605 and keeps an Overweight rating on the shares. The company’s 2024 outlook was well received and bakes in 5% pricing and 4% volume gains, both above expectations, the analyst tells investors in a research note.